-
Ranolazine has gained expanded approval from the FDA for the treatment of chronic angina.
-
The ECG shown above was obtained from a 60-year-old woman who presented with an acute stroke. Is her ECG consistent with this diagnosis, and/or suggestive of something more?
-
The first new urate-lowering drug has been approved in more than 40 years.
-
A prospective study of men and women showed that duration of sleep is correlated with coronary artery calcification with 1 hour more of sleep daily reducing the odds of calcification over 5 years by 33%.
-
Utilizing genotyping for warfarin therapy in patients with non-valvular atrial fibrillation may not be cost-effective.
-
Proton pump inhibitors given concomitantly with clopidogrel administered after acute myocardial infarction appear to diminish the beneficial effects of clopidogrel, thus increasing the risk of re-infarction.
-
Evaluation of the clinical course of the 21,094 eligible U.S. male physicians in the Physicians' Health Study revealed that an elevated BMI in both pre-obese and obese subjects was associated with an increased risk of CHF and that vigorous physical activity was associated with a decreased risk of CHF.
-
For persons aged 65 or older in the United States, congestive heart failure (CHF) remains the most common diagnosis for hospital admission.
-
In older women and men, all low-trauma fractures were associated with increased mortality risk for at least 5 years. Subsequent fracture increased that risk.
-
Eltrombopag is a thrombopoietin (TPO) receptor agonist approved by the FDA for the treatment of thrombocytopenia.
